An Unfortunate Step for MannKind As Its Stock Plunges Over Partnership Uncertainty
This article was originally published in The Pink Sheet Daily
Executive Summary
Some analysts see more market opportunity for the company's inhaled Phase I GLP-1 drug than the Afresa insulin inhaler.
You may also be interested in...
New MannKind Data Appear Positive, But Doubts Persist About Afrezza's Viability
Pulmonary function data don't resolve questions about safety, analysts argue.
New MannKind Data Appear Positive, But Doubts Persist About Afrezza's Viability
Pulmonary function data don't resolve questions about safety, analysts argue.
MannKind CEO Is Optimistic About Near-Term Approval of Afrezza
One industry watcher at the J.P. Morgan conference says the company is like a "teenager," there's always an explanation.